case_images: PMC5059539_01
case_images: Case #1 of a 71-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c), within 3 months after completion of Radium-223 (d, e, f), and 6-12 months after Radium-223 (g, h, i). Imaging findings are summarized in Table 1.
case_images: IJMI2016-2568031.001.jpg
case_images: PMC5059539_01_IJMI2016-2568031.001.jpg
case_images: fig1
case_images: PMC5059539_02
case_images: Case #2 of a 65-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c), within 3 months after completion of Radium-223 (d, e, f), and 6-12 months after Radium-223 (g, h, i). Imaging findings are summarized in Table 2.
case_images: IJMI2016-2568031.002.jpg
case_images: PMC5059539_02_IJMI2016-2568031.002.jpg
case_images: fig2
case_images: The patient died 19 months after Radium-223 therapy with progressive bone metastasis as well as visceral metastases and lymphadenopathy (Figure 2, Table 2).
case_images: PMC5059539_03
case_images: Case #3 of a 67-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c) and within 3 months after completion of Radium-223 (d, e, f). Imaging findings are summarized in Table 3.
case_images: IJMI2016-2568031.003.jpg
case_images: PMC5059539_03_IJMI2016-2568031.003.jpg
case_images: fig3
case_images: Hb 8.5 mg/dL within three months of completion of Radium-223 and was found to have progressive disease involving the bone, liver, lymph nodes, lungs, and brain (Figure 3, Table 3). He was then treated with low-dose, daily cyclophosphamide (Cytoxan) and degarelix (Firmagon) but died five months after Radium-223 therapy.